Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India

CompletedOBSERVATIONAL
Enrollment

17,292

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Enteric FeverTyphoid FeverSalmonella Typhi Infection
Interventions
BIOLOGICAL

Typhoid Conjugate Vaccine

Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited

Trial Locations (6)

Unknown

D. Y. Patil Medical College and Hospital, Nerul, Navi Mumbai

Dr. Joshi's Central Clinical Microbiology Laboratory, Vashi, Navi Mumbai

Dr. Yewale Multispecialty Hospital for Children, Vashi, Navi Mumbai

Mahatma Gandhi Memorial (MGM) New Bombay Hospital, Vashi, Navi Mumbai

Mathadi Hospital Trust, Koparkharaine, Navi Mumbai

Navi Mumbai Municipal Corporation (NMMC) General Hospital, First Referral Unit (FRU), Vashi, Navi Mumbai

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

collaborator

World Health Organization

OTHER

collaborator

National Institute of Cholera and Enteric Diseases, India

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Stanford University

OTHER

NCT03554213 - Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India | Biotech Hunter | Biotech Hunter